1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Derm going generic?

Discussion in 'Dermatology' started by anonymous, Jul 16, 2019 at 8:00 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    My company is pushing nothing but generics and hanging on to old branded products with no coverage. Seems we are all competing for the generic market share now. Is it to leave derm behind? Hard to see a future in derm with no innovation. Major Layoffs and more generics are all I’ve seen over the past few years in this space.
     

  2. anonymous

    anonymous Guest

    Expect it to continue that way. Managed care has changed everything. The cheapest products win every time.